多家恒旭资本投资企业获评投资界2020年Venture50榜单_Partners_News

多家恒旭资本投资企业获评投资界2020年Venture50榜单

2020-12-14

近日，投资界发布2020年Venture50风云榜及五大行业榜单，恒旭资本投资企业震坤行、高诚生物获选风云榜50强，长风药业、瑞博生物、德美医疗、高诚生物获选大健康行业50强。

Venture50（简称V50），由清科集团自2006年创办至今。历经十余年的发展与升华，本评选已成为高成长企业投资风向标。并针对企业不同发展阶段，设立风云榜和新芽榜，聚集万家创业项目、邀数百家投资机构、逾千位投资人评审，为创业企业和投资机构打造多维互动平台，为众多创业项目带来资本助力。2020年增设五大行业榜单，从行业维度深度发掘具有行业风向标意义的未上市领军企业，带动资本对高成长企业的关注与发掘。

截至2020年11月统计，活动累计参选企业70000+，帮助企业融资超过270亿美元，近三年V50入榜企业后续融资率达67.4%，上市率约21%。发掘并见证了无数优秀创业企业从“新芽”成长为“独角兽”，促成资本支持产业落地、反哺实体经济的成功案例，全方位为创业创新创造厚植土壤。

Address：5th Floor, Building N3, New Bund Square City, No. 2, Lane 131, Qiantan Avenue, Pudong New District, Shanghai

Email：scir@hengxucapital.com

Change of Address Notice

Dear investors and partners,

With your ongoing care and support, Hengxu Capital has achieved significant development and progress since its establishment. In order to better meet the needs of our business operations, our office location will be relocated to 5F, Building N3, New Bund Square City, No. 2, Lane 131, Qiantan Avenue, Pudong New District, Shanghai(Map Link: https://j.map.baidu.com/b5/x7VK).

The new office space is conveniently located with excellent facilities, providing improved conditions for meetings, receptions, and work. This relocation will facilitate better communication and collaboration between Hengxu Capital and our partners, enhancing employee satisfaction and office efficiency, and laying a solid foundation for continued and rapid business development.

The new office has been officially in use since January 29, and our mailing address has been switched to the new location. Considering the approaching Chinese New Year, we will not hold a relocation ceremony at the moment but plan to invite you to visit and guide us at a suitable time in the future.

If you have any questions or concerns, please feel free to contact us. Our phone numbers and email addresses remain unchanged. Once again, we appreciate your support and understanding, and we look forward to creating a brighter future together.

Shanghai SAIC Hengxu Capital Co., Ltd.

Jan. 29, 2024